Database Query Results : , , TrxR1

TrxR1, thioredoxin reductase 1: Click to Expand ⟱
Source:
Type:
TrxR1 or TXNRD1 (Thioredoxin Reductase 1)
Redox Control, Stress Tolerance, and Therapy Resistance
• Many studies have found that an elevated expression of TrxR1 in breast tumors, NSCLC, HCC correlates with increased tumor aggressiveness and a poorer prognosis.
-TrxR1 expression was elevated by >50 fold in FaDu and HeLa cells, and by >20 fold in SCC-1 compared to either MSK-Leuk1 or keratinocytes.

High TXNRD1 expression often associates with:
-Advanced stage
-Therapy resistance
-Reduced survival

TrxR1 Inhibition
-Collapses redox control
-Causes rapid ROS accumulation
-Triggers apoptosis, especially in high-stress tumors


Scientific Papers found: Click to Expand⟱
1978- CUR,    Curcumin targeting the thioredoxin system elevates oxidative stress in HeLa cells
- in-vitro, Cerv, HeLa
TrxR1↓, ROS↑, DNA-PK↑, eff↑, Trx↓, Trx1↓,
1954- GamB,    Gambogic acid induces apoptosis in hepatocellular carcinoma SMMC-7721 cells by targeting cytosolic thioredoxin reductase
- in-vitro, HCC, SMMC-7721 cell
AntiTum↑, TrxR↓, TrxR1↓, ROS↑, Apoptosis↑, Dose∅, Dose?,
2902- HNK,  Rad,    Honokiol Mitigates Ionizing Radiation-Induced Injury by Maintaining the Redox Balance of the TrxR/Trx System
- in-vitro, Nor, BEAS-2B
*TrxR1↑, *Trx↑, *radioP↑, *ROS↓,
2873- HNK,    Honokiol Alleviates Oxidative Stress-Induced Neurotoxicity via Activation of Nrf2
- in-vitro, Nor, PC12
*neuroP↑, *GSH↑, *HO-1↑, *NADPH↑, *Trx1↑, *TrxR1↑, *NRF2↑, *ROS↓, *antiOx↑, *BBB↑, Dose↓,
2922- LT,    Combination of transcriptomic and proteomic approaches helps unravel the mechanisms of luteolin in inducing liver cancer cell death via targeting AKT1 and SRC
- in-vitro, Liver, HUH7
Half-Life↝, TumCCA↑, AKT1↓, ATF2↓, NF-kB↓, GSK‐3β↓, cMyc↓, GSTs↓, TrxR1↓, ROS↑,
1984- Part,    Targeting Thioredoxin Reductase by Parthenolide Contributes to Inducing Apoptosis of HeLa Cells
- in-vitro, Cerv, HeLa
AntiCan↑, TrxR1↓, TrxR2↓, ROS↑, Apoptosis↑, eff↓, eff↑,
1944- PL,    Piperlongumine, a Novel TrxR1 Inhibitor, Induces Apoptosis in Hepatocellular Carcinoma Cells by ROS-Mediated ER Stress
- in-vitro, HCC, HUH7 - in-vitro, HCC, HepG2
ER Stress↑, TrxR1↓, ROS↑, eff↓, Bcl-2↓, proCasp3↓, BAX↓, cl‑Casp3↑, TumCCA↑, p‑PERK↑, ATF4↑, TumCG↓, lipid-P↑, selectivity↑,
1947- PL,    Piperlongumine as a direct TrxR1 inhibitor with suppressive activity against gastric cancer
- in-vitro, GC, SGC-7901 - in-vitro, GC, NA
TrxR1↓, ROS↑, ER Stress↑, mtDam↑, selectivity↑, NO↑, TumCCA↑, mt-ROS↑, Casp9↑, Bcl-2↓, Bcl-xL↓, cl‑PARP↑, eff↓, lipid-P↑,
2950- PL,    Overview of piperlongumine analogues and their therapeutic potential
- Review, Var, NA
AntiAg↑, neuroP↑, Inflam↓, NO↓, PGE2↓, MMP3↓, MMP13↓, TumCMig↓, TumCI↓, p38↑, JNK↑, NF-kB↑, ROS↑, FOXM1↓, TrxR1↓, GSH↓, Trx↓, cMyc↓, Casp3↑, Bcl-2↓, Mcl-1↓, STAT3↓, AR↓, DNAdam↑,
2943- PL,    Piperlongumine Inhibits Thioredoxin Reductase 1 by Targeting Selenocysteine Residues and Sensitizes Cancer Cells to Erastin
- in-vitro, CRC, HCT116 - in-vitro, Lung, A549 - in-vitro, BC, MCF-7
TrxR1?, TumCD↑, ROS↑, GSH↓, eff↑,
4736- Se,  SFN,    Synergy between sulforaphane and selenium in protection against oxidative damage in colonic CCD841 cells
- in-vitro, Nor, CCD841
*TrxR1↑, *H2O2↓, *NRF2↑,
3183- SFN,    Sulforaphane potentiates the efficacy of chemoradiotherapy in glioblastoma by selectively targeting thioredoxin reductase 1
- in-vitro, GBM, NA
RadioS↑, TrxR1↓, ROS↑, ChemoSen↑, Prx↓,
2355- SK,    Pharmacological properties and derivatives of shikonin-A review in recent years
- Review, Var, NA
AntiCan↑, TumCP↓, TumCMig↓, Apoptosis↑, TumAuto↑, Necroptosis↑, ROS↑, TrxR1↓, PKM2↓, RIP1↓, RIP3↓, Src↓, FAK↓, PI3K↓, Akt↓, mTOR↓, GRP58↓, MMPs↓, ATF2↓, cl‑PARP↑, Casp3↑, p‑p38↑, p‑JNK↑, p‑ERK↓,
2200- SK,    Shikonin inhibits the growth of anaplastic thyroid carcinoma cells by promoting ferroptosis and inhibiting glycolysis
- in-vitro, Thyroid, CAL-62 - in-vitro, Thyroid, 8505C
NF-kB↓, GPx4↓, TrxR1↓, PKM2↓, GLUT1↓, Glycolysis↓, Ferroptosis↑, GlucoseCon↓, lactateProd↓, ROS↑,
2196- SK,    Research progress in mechanism of anticancer action of shikonin targeting reactive oxygen species
- Review, Var, NA
*ALAT↓, *AST↓, *Inflam?, *EMT↑, ROS?, TrxR1↓, PERK↑, eIF2α↑, ATF4↑, CHOP↑, IRE1↑, JNK↑, eff↝, DR5↑, Glycolysis↓, PKM2↓, ChemoSen↑, GPx4↓, HO-1↑,
1908- SNP,    Exposure to Silver Nanoparticles Inhibits Selenoprotein Synthesis and the Activity of Thioredoxin Reductase
- in-vitro, Lung, A549
TrxR↓, TrxR1↓, ROS↑, ER Stress↑, TumCP↓, selenoP↓,

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 16

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

Ferroptosis↑, 1,   GPx4↓, 2,   GSH↓, 2,   GSTs↓, 1,   HO-1↑, 1,   lipid-P↑, 2,   Prx↓, 1,   ROS?, 1,   ROS↑, 12,   mt-ROS↑, 1,   selenoP↓, 1,   Trx↓, 2,   Trx1↓, 1,   TrxR↓, 2,   TrxR1?, 1,   TrxR1↓, 12,   TrxR2↓, 1,  

Mitochondria & Bioenergetics ⓘ

mtDam↑, 1,  

Core Metabolism/Glycolysis ⓘ

AKT1↓, 1,   cMyc↓, 2,   GlucoseCon↓, 1,   Glycolysis↓, 2,   lactateProd↓, 1,   PKM2↓, 3,  

Cell Death ⓘ

Akt↓, 1,   Apoptosis↑, 3,   ATF2↓, 2,   BAX↓, 1,   Bcl-2↓, 3,   Bcl-xL↓, 1,   Casp3↑, 2,   cl‑Casp3↑, 1,   proCasp3↓, 1,   Casp9↑, 1,   DR5↑, 1,   Ferroptosis↑, 1,   GRP58↓, 1,   JNK↑, 2,   p‑JNK↑, 1,   Mcl-1↓, 1,   Necroptosis↑, 1,   p38↑, 1,   p‑p38↑, 1,   RIP1↓, 1,   TumCD↑, 1,  

Protein Folding & ER Stress ⓘ

CHOP↑, 1,   eIF2α↑, 1,   ER Stress↑, 3,   IRE1↑, 1,   PERK↑, 1,   p‑PERK↑, 1,  

Autophagy & Lysosomes ⓘ

TumAuto↑, 1,  

DNA Damage & Repair ⓘ

DNA-PK↑, 1,   DNAdam↑, 1,   cl‑PARP↑, 2,  

Cell Cycle & Senescence ⓘ

TumCCA↑, 3,  

Proliferation, Differentiation & Cell State ⓘ

p‑ERK↓, 1,   FOXM1↓, 1,   GSK‐3β↓, 1,   mTOR↓, 1,   PI3K↓, 1,   Src↓, 1,   STAT3↓, 1,   TumCG↓, 1,  

Migration ⓘ

AntiAg↑, 1,   FAK↓, 1,   MMP13↓, 1,   MMP3↓, 1,   MMPs↓, 1,   RIP3↓, 1,   TumCI↓, 1,   TumCMig↓, 2,   TumCP↓, 2,  

Angiogenesis & Vasculature ⓘ

ATF4↑, 2,   NO↓, 1,   NO↑, 1,  

Barriers & Transport ⓘ

GLUT1↓, 1,  

Immune & Inflammatory Signaling ⓘ

Inflam↓, 1,   NF-kB↓, 2,   NF-kB↑, 1,   PGE2↓, 1,  

Hormonal & Nuclear Receptors ⓘ

AR↓, 1,  

Drug Metabolism & Resistance ⓘ

ChemoSen↑, 2,   Dose?, 1,   Dose↓, 1,   Dose∅, 1,   eff↓, 3,   eff↑, 3,   eff↝, 1,   Half-Life↝, 1,   RadioS↑, 1,   selectivity↑, 2,  

Clinical Biomarkers ⓘ

AR↓, 1,   FOXM1↓, 1,  

Functional Outcomes ⓘ

AntiCan↑, 2,   AntiTum↑, 1,   neuroP↑, 1,  
Total Targets: 97

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

antiOx↑, 1,   GSH↑, 1,   H2O2↓, 1,   HO-1↑, 1,   NRF2↑, 2,   ROS↓, 2,   Trx↑, 1,   Trx1↑, 1,   TrxR1↑, 3,  

Core Metabolism/Glycolysis ⓘ

ALAT↓, 1,   NADPH↑, 1,  

Proliferation, Differentiation & Cell State ⓘ

EMT↑, 1,  

Barriers & Transport ⓘ

BBB↑, 1,  

Immune & Inflammatory Signaling ⓘ

Inflam?, 1,  

Clinical Biomarkers ⓘ

ALAT↓, 1,   AST↓, 1,  

Functional Outcomes ⓘ

neuroP↑, 1,   radioP↑, 1,  
Total Targets: 18

Scientific Paper Hit Count for: TrxR1, thioredoxin reductase 1
4 Piperlongumine
3 Shikonin
2 Honokiol
2 Sulforaphane (mainly Broccoli)
1 Curcumin
1 Gambogic Acid
1 Radiotherapy/Radiation
1 Luteolin
1 Parthenolide
1 Selenium
1 Silver-NanoParticles
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:1207  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page